William C Chen1, Joe D Baal2, Ulysis Baal2, Jonathan Pai3, Alexander Gottschalk4, Lauren Boreta4, Steve E Braunstein4, David R Raleigh5. 1. Department of Radiation Oncology, University of California San Francisco, California. Electronic address: William.Chen@ucsf.edu. 2. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. 3. Department of Internal Medicine, University of Southern California, Los Angeles, California. 4. Department of Radiation Oncology, University of California San Francisco, California. 5. Department of Radiation Oncology, University of California San Francisco, California; Department of Neurological Surgery, University of California San Francisco, San Francisco, California. Electronic address: david.raleigh@ucsf.edu.
Abstract
PURPOSE: To perform a systematic review and pooled meta-analysis of adrenal metastasis stereotactic body radiation therapy (SBRT) outcomes, treatment characteristics, and toxicity to define the efficacy and propose guidelines for intervention. METHODS AND MATERIALS: We performed a comprehensive literature search of the Embase and PubMed databases of studies reporting outcome or toxicity data for photon-based SBRT of adrenal metastases in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We then conducted a meta-analysis to estimate pooled overall response, local control (LC), and overall survival and analyzed these outcomes in the context of dosimetric parameters and toxicity using metaregression. RESULTS: Thirty-nine studies published between 2009 and 2019 reporting outcomes on 1006 patients were included. The median follow-up was 12 months, and the median biological equivalent dose (BED10, alpha/beta = 10) was 67 Gy. The pooled overall response was 54.6% (95% confidence interval [CI], 46.5%-62.5%). The pooled 1- and 2-year rates of LC were 82% (95% CI, 74%-88%) and 63% (95% CI, 50%-74%), respectively, and the pooled 1- and 2-year overall survival rates were 66% (95% CI, 57%-74%) and 42% (95% CI, 31%-53%), respectively. There was a strong positive association between SBRT dose and 1- and 2-year LC (P < .0001, P = .0002) and an association with 2-year OS (P = .03). Based on a metaregression of dose and LC, BED10 of 60 Gy, 80 Gy, and 100 Gy predicted 1-year LC of 70.5%, 84.8%, and 92.9% and 2-year LC of 47.8%, 70.1%, and 85.6%, respectively. The overall rate of grade 3 or higher toxicity was 1.8%. CONCLUSIONS: SBRT of adrenal metastases provides good 1-year LC with an excellent safety profile, and dose escalation may be associated with improved LC. Prospective studies are needed to validate these findings and determine whether there are subsets of patients for whom adrenal metastasis-directed SBRT may confer a survival advantage. Published by Elsevier Inc.
PURPOSE: To perform a systematic review and pooled meta-analysis of adrenal metastasis stereotactic body radiation therapy (SBRT) outcomes, treatment characteristics, and toxicity to define the efficacy and propose guidelines for intervention. METHODS AND MATERIALS: We performed a comprehensive literature search of the Embase and PubMed databases of studies reporting outcome or toxicity data for photon-based SBRT of adrenal metastases in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We then conducted a meta-analysis to estimate pooled overall response, local control (LC), and overall survival and analyzed these outcomes in the context of dosimetric parameters and toxicity using metaregression. RESULTS: Thirty-nine studies published between 2009 and 2019 reporting outcomes on 1006 patients were included. The median follow-up was 12 months, and the median biological equivalent dose (BED10, alpha/beta = 10) was 67 Gy. The pooled overall response was 54.6% (95% confidence interval [CI], 46.5%-62.5%). The pooled 1- and 2-year rates of LC were 82% (95% CI, 74%-88%) and 63% (95% CI, 50%-74%), respectively, and the pooled 1- and 2-year overall survival rates were 66% (95% CI, 57%-74%) and 42% (95% CI, 31%-53%), respectively. There was a strong positive association between SBRT dose and 1- and 2-year LC (P < .0001, P = .0002) and an association with 2-year OS (P = .03). Based on a metaregression of dose and LC, BED10 of 60 Gy, 80 Gy, and 100 Gy predicted 1-year LC of 70.5%, 84.8%, and 92.9% and 2-year LC of 47.8%, 70.1%, and 85.6%, respectively. The overall rate of grade 3 or higher toxicity was 1.8%. CONCLUSIONS:SBRT of adrenal metastases provides good 1-year LC with an excellent safety profile, and dose escalation may be associated with improved LC. Prospective studies are needed to validate these findings and determine whether there are subsets of patients for whom adrenal metastasis-directed SBRT may confer a survival advantage. Published by Elsevier Inc.
Authors: Nicholas B Figura; Daniel E Oliver; Homan Mohammadi; Kaylee Martinez; George D Grass; Sarah E Hoffe; Peter A S Johnstone; Jessica M Frakes Journal: Am J Clin Oncol Date: 2020-02 Impact factor: 2.339
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: J Clin Epidemiol Date: 2009-07-23 Impact factor: 6.437
Authors: Sonali Rudra; Renuka Malik; Mark C Ranck; Karl Farrey; Daniel W Golden; Michael D Hasselle; Ralph R Weichselbaum; Joseph K Salama Journal: Technol Cancer Res Treat Date: 2013-01-25
Authors: Kyle E Rusthoven; Brian D Kavanagh; Higinia Cardenes; Volker W Stieber; Stuart H Burri; Steven J Feigenberg; Mark A Chidel; Thomas J Pugh; Wilbur Franklin; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: John Conibear; Brendan Chia; Yenting Ngai; Andrew Tom Bates; Nicholas Counsell; Rushil Patel; David Eaton; Corinne Faivre-Finn; John Fenwick; Martin Forster; Gerard G Hanna; Susan Harden; Philip Mayles; Syed Moinuddin; David Landau Journal: BMJ Open Date: 2018-04-17 Impact factor: 2.692
Authors: Felix Ehret; David Kaul; Markus Kufeld; Clara Vom Endt; Volker Budach; Carolin Senger; Christoph Fürweger; Alfred Haidenberger; Alexander Muacevic Journal: J Cancer Res Clin Oncol Date: 2022-03-15 Impact factor: 4.553
Authors: Tugce Kutuk; Robert Herrera; Teuta Z Mustafayev; Gorkem Gungor; Gamze Ugurluer; Banu Atalar; Rupesh Kotecha; Matthew D Hall; Muni Rubens; Kathryn E Mittauer; Jessika A Contreras; James McCulloch; Noah S Kalman; Diane Alvarez; Tino Romaguera; Alonso N Gutierrez; Jacklyn Garcia; Adeel Kaiser; Minesh P Mehta; Enis Ozyar; Michael D Chuong Journal: Adv Radiat Oncol Date: 2022-04-25
Authors: Priscilla K Stumpf; Ellen D Yorke; Issam El Naqa; Kyle C Cuneo; Jimm Grimm; Karyn A Goodman Journal: Int J Radiat Oncol Biol Phys Date: 2021-05-01 Impact factor: 8.013
Authors: A Baydoun; H Chen; I Poon; S Badellino; R Dagan; D Erler; M C Foote; A V Louie; K J Redmond; U Ricardi; A Sahgal; T Biswas Journal: Clin Transl Radiat Oncol Date: 2021-10-26
Authors: Alicia Román-Jobacho; María Hernández-Miguel; María Jesús García-Anaya; Jaime Gómez-Millán; J A Medina-Carmona; Ana Otero-Romero Journal: J Clin Transl Res Date: 2021-05-27